These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 20431558)
41. Potential Reuse of Oncology Drugs in the Treatment of Rare Diseases. Liu Z; Fang H; Slikker W; Tong W Trends Pharmacol Sci; 2016 Oct; 37(10):843-857. PubMed ID: 27461952 [TBL] [Abstract][Full Text] [Related]
42. [Tasks and expectations for drug design based on pharmacogenomics]. Uyama Y Nihon Yakurigaku Zasshi; 2005 Dec; 126(6):432-5. PubMed ID: 16463462 [No Abstract] [Full Text] [Related]
43. Pharmacogenetics and pharmacogenomics as tools in cancer therapy. Rodríguez-Vicente AE; Lumbreras E; Hernández JM; Martín M; Calles A; Otín CL; Algarra SM; Páez D; Taron M Drug Metab Pers Ther; 2016 Mar; 31(1):25-34. PubMed ID: 26863347 [TBL] [Abstract][Full Text] [Related]
47. Anticipating designer drug-resistant cancer cells. Frangione ML; Lockhart JH; Morton DT; Pava LM; Blanck G Drug Discov Today; 2015 Jul; 20(7):790-3. PubMed ID: 25697478 [TBL] [Abstract][Full Text] [Related]
48. New targets and challenges in the molecular therapeutics of cancer. Eastman A; Perez RP Br J Clin Pharmacol; 2006 Jul; 62(1):5-14. PubMed ID: 16842374 [TBL] [Abstract][Full Text] [Related]
49. Marking off new territory in the search for anticancer compounds: epigenetic mechanisms add complexity and promise to cancer research efforts. Nelson B Cancer Cytopathol; 2012 Jun; 120(3):143-4. PubMed ID: 22692980 [No Abstract] [Full Text] [Related]
50. Challenges ahead for companion diagnostics. Schmidt C J Natl Cancer Inst; 2012 Jan; 104(1):14-5. PubMed ID: 22173588 [No Abstract] [Full Text] [Related]
52. Molecular tools for companion diagnostics. Zieba A; Grannas K; Söderberg O; Gullberg M; Nilsson M; Landegren U N Biotechnol; 2012 Sep; 29(6):634-40. PubMed ID: 22634023 [TBL] [Abstract][Full Text] [Related]
53. [Value and applications of pharmacogenetics in oncology and hematology]. Albin N; Massade L; Gouyette A Bull Cancer; 1997 Jun; 84(6):643-51. PubMed ID: 9295869 [TBL] [Abstract][Full Text] [Related]
54. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176 [TBL] [Abstract][Full Text] [Related]
55. Modern molecular approaches to drug design and discovery. Ojima I Acc Chem Res; 2008 Jan; 41(1):2-3. PubMed ID: 18193819 [No Abstract] [Full Text] [Related]
56. [Personalized treatment of cancer: utopia or chance?]. Thiel E Dtsch Med Wochenschr; 2010 Sep; 135(38):1851. PubMed ID: 20842603 [No Abstract] [Full Text] [Related]
58. Cancer robustness: tumour tactics. Kitano H Nature; 2003 Nov; 426(6963):125. PubMed ID: 14614483 [No Abstract] [Full Text] [Related]
59. An interview with Dr. Edward Abrahams on companion and complementary diagnostics in the era of personalized medicine. Abrahams E Expert Rev Mol Diagn; 2020 Jun; 20(6):561-563. PubMed ID: 32148107 [No Abstract] [Full Text] [Related]
60. SRC as a potential therapeutic target in solid tumor oncology. Gallick GE Clin Adv Hematol Oncol; 2004 Jul; 2(7):435-7. PubMed ID: 16163218 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]